A multicenter randomised study comparing the efficacy of adefovir dipivoxil versus pegylated interferon alpha-2a plus placebo versus adefovir dipivoxil plus peglyated interferon alpha-2a for the treatment of chronic delta hepatitis.

Trial Profile

A multicenter randomised study comparing the efficacy of adefovir dipivoxil versus pegylated interferon alpha-2a plus placebo versus adefovir dipivoxil plus peglyated interferon alpha-2a for the treatment of chronic delta hepatitis.

Completed
Phase of Trial: Phase III

Latest Information Update: 27 Jan 2011

At a glance

  • Drugs Adefovir dipivoxil; Peginterferon alfa-2a
  • Indications Hepatitis D
  • Focus Therapeutic Use
  • Acronyms DELTA; HEP-NET; HID-IT; HIDIT
  • Most Recent Events

    • 27 Jan 2011 Results published in New England Journal of Medicine
    • 26 Sep 2009 Status changed from active, no longer recruiting to completed as reported by ISRCTN: Current Controlled Trials.
    • 13 Dec 2006 Status change
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top